Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
Subscribe To Our Newsletter & Stay Updated
